NAD+ therapy research
Pro Research Analysisby 
Searched over 200M research papers
NAD+ Therapy and Age-Related Degenerative Diseases
NAD+ (nicotinamide adenine dinucleotide) is a vital molecule involved in energy production, DNA repair, gene expression, and cell signaling. Research shows that NAD+ levels decline with age and in age-related diseases, contributing to oxidative stress, inflammation, and mitochondrial dysfunction. Supplementing with NAD+ precursors—such as nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinamide (NAM), and niacin—has shown promise in animal models for improving healthspan, reducing disease symptoms, and potentially extending lifespan. These benefits are especially notable in conditions like neurodegeneration, metabolic syndrome, and cardiovascular disease Braidy2020Braidy2019Iqbal2024+4 MORE.
NAD+ Precursors: Mechanisms and Therapeutic Potential
NAD+ can be synthesized through several pathways, including the kynurenine pathway and salvage pathways using precursors like NR, NMN, NAM, and NA. Supplementation with these precursors effectively raises NAD+ levels in tissues, which can protect against age-related decline and disease by supporting mitochondrial function, reducing oxidative damage, and enhancing sirtuin activity—a family of proteins linked to longevity and cellular health Braidy2020Braidy2019Iqbal2024+4 MORE.
Clinical and Preclinical Evidence for NAD+ Therapy
Most evidence for the benefits of NAD+ therapy comes from preclinical studies in animal models, where supplementation with NAD+ precursors has improved outcomes in diseases such as Alzheimer’s, diabetes, stroke, and traumatic brain injury. In these models, NAD+ repletion has been shown to extend healthspan, improve cognitive function, and mitigate metabolic and neurodegenerative diseases Braidy2020Campbell2022Braidy2019+4 MORE. Early clinical studies in humans have demonstrated that NAD+ precursor supplementation can increase NAD+ levels in tissues, but the clinical benefits for disease treatment are still limited and require further investigation Braidy2020Gilmour2020Iqbal2024+1 MORE.
NAD+ Therapy in Metabolic Diseases
NAD+ therapy has shown particular promise in metabolic diseases. For example, NR supplementation in both mice and humans increased levels of the exercise-linked hormone irisin (Fndc5), which helped reverse nonalcoholic fatty liver disease (NAFLD) by improving mitochondrial function, reducing inflammation, and stabilizing Fndc5 protein through SIRT2-dependent mechanisms. This suggests a link between NAD+ therapy, exercise benefits, and metabolic health .
Safety, Risks, and Future Directions
NAD+ precursors generally have a favorable safety profile in acute settings, but long-term effects in humans are not well understood. Potential risks include the accumulation of toxic metabolites, increased risk of tumorigenesis, and promotion of cellular senescence. There is also growing interest in the role of gut microbiota in NAD+ metabolism, as orally administered NAD+ intermediates interact with gut bacteria, potentially influencing therapy outcomes Braidy2020Iqbal2024Reiten2021.
Conclusion
NAD+ therapy, particularly through supplementation with precursors like NR and NMN, holds significant promise for treating age-related diseases and improving healthspan. While animal studies are encouraging, more robust and long-term clinical trials are needed to confirm these benefits and clarify safety in humans. Understanding individual differences in NAD+ metabolism and the influence of gut microbiota will be important for optimizing future therapies Braidy2020Braidy2019Gilmour2020+3 MORE.
Sources and full results
Most relevant research papers on this topic